RARE
Ultragenyx Pharmaceutical, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ultragenyx.com
- Employees(FY) 1311
- ISIN US90400D1081
Performance
-2.3%
1W
-17.28%
1M
-7.05%
3M
+9.14%
6M
-13.09%
YTD
-11.67%
1Y
Profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Investment Analysis Report: RARE
Overview
In this investment analysis report, we will analyze the stock of RARE, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will delve into the financial health, earnings and revenue growth, profitability, operating margin, operating cash flow analysis, and c...
Technical Analysis of RARE 2024-05-03
Overview:
In analyzing the technical indicators for RARE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...
Recent News & Updates
- 2024-05-07 16:30
- 2024-05-07 04:30
- 2024-05-04 10:24
- 2024-05-04 10:05
- 2024-05-03 22:24
- 2024-05-03 15:01
- 2024-05-03 12:22
- 2024-05-03 00:22
- 2024-05-02 17:49
- 2024-05-02 16:08
Ultragenyx: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-02 16:00
- 2024-05-02 08:58
- 2024-05-02 08:00
- 2024-05-02 05:10
- 2024-05-02 04:00
- 2024-04-30 16:00
- 2024-04-30 08:00
- 2024-04-30 04:00
- 2024-04-29 20:00
- 2024-04-25 16:30
- 2024-04-25 04:30
- 2024-04-19 16:30
- 2024-04-19 04:30
- 2024-04-16 11:33
- 2024-04-15 23:33
- 2024-04-15 07:30
- 2024-04-15 07:00
- 2024-04-14 19:00
- 2024-04-12 16:22
- 2024-04-12 08:00
Page 1 of 7
previousnext